Physiological and pathological functions of neuroserpin: Regulation of cellular responses through multiple mechanisms

Seminars in Cell and Developmental Biology

Volumn 62, Issue , 2017, Pages 152-159

  Lee, Tet Woo ^a   Tsang, Vicky W K ^a   Loef, Evert Jan ^a,b   Birch, Nigel P ^a,c  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c Bioactives Research New Zealand   (New Zealand)

Author keywords

Alzheimer's disease; Brain cancer; Neuroprotection; Protease inhibitor; Synaptic plasticity; Tissue plasminogen activator

Indexed keywords

NEUROSERPIN; TISSUE PLASMINOGEN ACTIVATOR; NEUROPEPTIDE; SERINE PROTEINASE INHIBITOR;

ALZHEIMER DISEASE; BEHAVIOR; BRAIN BLOOD VESSEL; BRAIN CANCER; BRAIN DISEASE; CELL FUNCTION; CELL SURVIVAL; COMPLEX FORMATION; DEGENERATIVE DISEASE; ENDOCRINE CELL; FAMILIAL DISEASE; FAMILIAL ENCEPHALOPATHY WITH NEUROSERPIN INCLUSION BODIES; GENE MUTATION; HUMAN; IMMUNOCOMPETENT CELL; NERVE CELL; NERVE CELL PLASTICITY; NEUROPATHOLOGY; NONHUMAN; PHYSIOLOGICAL PROCESS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; PROTEIN STRUCTURE; REGULATORY MECHANISM; REVIEW; ANIMAL; BIOLOGICAL MODEL; CELLS; CHEMISTRY; DISEASES; METABOLISM;

ANIMALS; CELLS; DISEASE; HUMANS; MODELS, BIOLOGICAL; NEUROPEPTIDES; PROTEOLYSIS; SERPINS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 85010934302     PISSN: 10849521     EISSN: 10963634     Source Type: Journal    
DOI: 10.1016/j.semcdb.2016.09.007     Document Type: Review

References (85)

1. [1] Osterwalder, T., Contartese, J., Stoeckli, E.T., Kuhn, T.B., Sonderegger, P., Neuroserpin, an axonally secreted serine protease inhibitor. EMBO J. 15:12 (1996), 2944–2953.
2. [2] Olson, S.T., Gettins, P.G., Regulation of proteases by protein inhibitors of the serpin superfamily. Prog. Mol. Biol. Transl. Sci. 99 (2011), 185–240.
3. [3] Hastings, G.A., Coleman, T.A., Haudenschild, C.C., Stefansson, S., Smith, E.P., Barthlow, R., Cherry, S., Sandkvist, M., Lawrence, D.A., Neuroserpin, a brain-associated inhibitor of tissue plasminogen activator is localized primarily in neurons. Implications for the regulation of motor learning and neuronal survival. J. Biol. Chem. 272:52 (1997), 33062–33067.
4. [4] Osterwalder, T., Cinelli, P., Baici, A., Pennella, A., Krueger, S.R., Schrimpf, S.P., Meins, M., Sonderegger, P., The axonally secreted serine proteinase inhibitor, neuroserpin, inhibits plasminogen activators and plasmin but not thrombin. J. Biol. Chem. 273:4 (1998), 2312–2321.
5. [5] Krueger, S.R., Ghisu, G.P., Cinelli, P., Gschwend, T.P., Osterwalder, T., Wolfer, D.P., Sonderegger, P., Expression of neuroserpin, an inhibitor of tissue plasminogen activator, in the developing and adult nervous system of the mouse. J. Neurosci. 17:23 (1997), 8984–8996.
6. [6] Teesalu, T., Kulla, A., Simisker, A., Siren, V., Lawrence, D.A., Asser, T., Vaheri, A., Tissue plasminogen activator and neuroserpin are widely expressed in the human central nervous system. Thromb. Haemost. 92:2 (2004), 358–368.
7. [7] Miranda, E., Lomas, D.A., Neuroserpin: a serpin to think about. Cell. Mol. Life Sci. 63:6 (2006), 709–722.
8. [8] Cinelli, P., Madani, R., Tsuzuki, N., Vallet, P., Arras, M., Zhao, C.N., Osterwalder, T., Rulicke, T., Sonderegger, P., Neuroserpin, a neuroprotective factor in focal ischemic stroke. Mol. Cell. Neurosci. 18:5 (2001), 443–457.
9. [9] Yamada, M., Takahashi, K., Ukai, W., Hashimoto, E., Saito, T., Yamada, M., Neuroserpin is expressed in early stage of neurogenesis in adult rat hippocampus. Neuroreport 21:2 (2010), 138–142.
10. [10] Hill, R.M., Parmar, P.K., Coates, L.C., Mezey, E., Pearson, J.F., Birch, N.P., Neuroserpin is expressed in the pituitary and adrenal glands and induces the extension of neurite-like processes in AtT-20 cells. Biochem. J. 345:Pt. 3 (2000), 595–601.
11. [11] de Groot, D.M., Pol, C., Martens, G.J., Comparative analysis and expression of neuroserpin in Xenopus laevis. Neuroendocrinology 82:1 (2005), 11–20.
12. [12] Tischler, A.S., Chromaffin cells as models of endocrine cells and neurons. Ann. N. Y. Acad. Sci. 971 (2002), 366–370.
13. [13] Gveric, D., Herrera, B., Petzold, A., Lawrence, D.A., Cuzner, M.L., Impaired fibrinolysis in multiple sclerosis: a role for tissue plasminogen activator inhibitors. Brain 126:Pt. 7 (2003), 1590–1598.
14. [14] Kennedy, S.A., van Diepen, A.C., van den Hurk, C.M., Coates, L.C., Lee, T.W., Ostrovsky, L.L., Miranda, E., Perez, J., Davies, M.J., Lomas, D.A., Dunbar, P.R., Birch, N.P., Expression of the serine protease inhibitor neuroserpin in cells of the human myeloid lineage. Thromb. Haemost. 97:3 (2007), 394–399.
15. [15] Munuswamy-Ramanujam, G., Dai, E., Liu, L., Shnabel, M., Sun, Y.M., Bartee, M., Lomas, D.A., Lucas, A.R., Neuroserpin, a thrombolytic serine protease inhibitor (serpin), blocks transplant vasculopathy with associated modification of T-helper cell subsets. Thromb. Haemost. 103:3 (2010), 545–555.
16. [16] Ambadapadi, S., Munuswamy-Ramanujam, G., Zheng, D., Sullivan, C., Dai, E., Morshed, S., McFadden, B., Feldman, E., Pinard, M., McKenna, R., Tibbetts, S., Lucas, A., Reactive center loop (RCL) peptides derived from serpins display independent coagulation and immune modulating activities. J. Biol. Chem. 291:6 (2016), 2874–2887.
17. [17] Zheng, D., Chen, H., Bartee, M.Y., Williams, J., Davids, J.A., Lomas, D.A., McFadden, G., Lucas, A.R., Myxomaviral anti-inflammatory serpin reduces myeloid-derived suppressor cells and human pancreatic cancer cell growth in mice. J. Cancer Sci. Ther. 5 (2013), 291–299.
18. [18] Lorenz, N., Loef, E.J., Verdon, D.J., Chen, C.J., Mansell, C.J., Angel, C.E., Brooks, A.E., Dunbar, P.R., Birch, N.P., Human T cell activation induces synaptic translocation and alters expression of the serine protease inhibitor neuroserpin and its target protease. J. Leukoc. Biol. 97:4 (2015), 699–710.
19. [19] Dustin, M.L., Colman, D.R., Neural and immunological synaptic relations. Science 298:5594 (2002), 785–789.
20. [20] Parmar, P.K., Coates, L.C., Pearson, J.F., Hill, R.M., Birch, N.P., Neuroserpin regulates neurite outgrowth in nerve growth factor-treated PC12 cells. J. Neurochem. 82:6 (2002), 1406–1415.
21. [21] Miranda, E., MacLeod, I., Davies, M.J., Perez, J., Romisch, K., Crowther, D.C., Lomas, D.A., The intracellular accumulation of polymeric neuroserpin explains the severity of the dementia FENIB. Hum. Mol. Genet. 17:11 (2008), 1527–1539.
22. [22] Lorenz, N., Loef, E.J., Kelch, I.D., Verdon, D.J., Black, M.M., Middleditch, M.J., Greenwood, D.R., Graham, E.S., Brooks, A.E., Dunbar, P.R., Birch, N.P., Plasmin and regulators of plasmin activity control the migratory capacity and adhesion of human T cells and dendritic cells by regulating cleavage of the chemokine CCL21. Immunol. Cell Biol., 2016, 10.1038/icb.2016.56.
23. [23] Madani, R., Kozlov, S., Akhmedov, A., Cinelli, P., Kinter, J., Lipp, H.P., Sonderegger, P., Wolfer, D.P., Impaired explorative behavior and neophobia in genetically modified mice lacking or overexpressing the extracellular serine protease inhibitor neuroserpin. Mol. Cell. Neurosci. 23:3 (2003), 473–494.
24. [24] Wannier-Morino, P., Rager, G., Sonderegger, P., Grabs, D., Expression of neuroserpin in the visual cortex of the mouse during the developmental critical period. Eur. J. Neurosci. 17:9 (2003), 1853–1860.
25. [25] Tsang, V.W., Young, D., During, M.J., Birch, N.P., AAV-mediated overexpression of neuroserpin in the hippocampus decreases PSD-95 expression but does not affect hippocampal-dependent learning and memory. PLoS One, 9(3), 2014, e91050.
26. [26] Lee, T.W., Tsang, V.W., Birch, N.P., Synaptic plasticity-associated proteases and protease inhibitors in the brain linked to the processing of extracellular matrix and cell adhesion molecules. Neuron Glia Biol. 4:3 (2008), 223–234.
27. [27] Lee, T.W., Tsang, V.W., Birch, N.P., Physiological and pathological roles of tissue plasminogen activator and its inhibitor neuroserpin in the nervous system. Front. Cell. Neurosci., 9, 2015, 396.
28. [28] Lynch, K.S., Ramsey, M.E., Cummings, M.E., The mate choice brain: comparing gene profiles between female choice and male coercive poeciliids. Genes Brain Behav. 11:2 (2012), 222–229.
29. [29] Ramsey, M.E., Maginnis, T.L., Wong, R.Y., Brock, C., Cummings, M.E., Identifying context-specific gene profiles of social, reproductive, and mate preference behavior in a fish species with female mate choice. Front. Neurosci., 6, 2012, 62.
30. [30] Navarro-Yubero, C., Cuadrado, A., Sonderegger, P., Munoz, A., Neuroserpin is post-transcriptionally regulated by thyroid hormone. Brain Res. Mol. Brain Res. 123:1–2 (2004), 56–65.
31. [31] Lee, T.W., Coates, L.C., Birch, N.P., Neuroserpin regulates N-cadherin-mediated cell adhesion independently of its activity as an inhibitor of tissue plasminogen activator. J. Neurosci. Res. 86:6 (2008), 1243–1253.
32. [32] Borges, V.M., Lee, T.W., Christie, D.L., Birch, N.P., Neuroserpin regulates the density of dendritic protrusions and dendritic spine shape in cultured hippocampal neurons. J. Neurosci. Res. 88:12 (2010), 2610–2617.
33. [33] Makarova, A., Mikhailenko, I., Bugge, T.H., List, K., Lawrence, D.A., Strickland, D.K., The low density lipoprotein receptor-related protein modulates protease activity in the brain by mediating the cellular internalization of both neuroserpin and neuroserpin-tissue-type plasminogen activator complexes. J. Biol. Chem. 278:50 (2003), 50250–50258.
34. [34] Shi, Y., Mantuano, E., Inoue, G., Campana, W.M., Gonias, S.L., Ligand binding to LRP1 transactivates Trk receptors by a Src family kinase-dependent pathway. Sci. Signal., 2(68), 2009, ra18.
35. [35] Bruno, M.A., Cuello, A.C., Activity-dependent release of precursor nerve growth factor, conversion to mature nerve growth factor, and its degradation by a protease cascade. Proc. Natl. Acad. Sci. U. S. A. 103:17 (2006), 6735–6740.
36. [36] Iulita, M.F., Do Carmo, S., Ower, A.K., Fortress, A.M., Aguilar, L.F., Hanna, M., Wisniewski, T., Granholm, A.C., Buhusi, M., Busciglio, J., Cuello, A.C., Nerve growth factor metabolic dysfunction in Down's syndrome brains. Brain 137:Pt. 3 (2014), 860–872.
37. [37] Chevilley, A., Lesept, F., Lenoir, S., Ali, C., Parcq, J., Vivien, D., Impacts of tissue-type plasminogen activator (tPA) on neuronal survival. Front. Cell. Neurosci., 9, 2015, 415.
38. [38] Yepes, M., Sandkvist, M., Wong, M.K., Coleman, T.A., Smith, E., Cohan, S.L., Lawrence, D.A., Neuroserpin reduces cerebral infarct volume and protects neurons from ischemia-induced apoptosis. Blood 96:2 (2000), 569–576.
39. [39] Zhang, Z., Zhang, L., Yepes, M., Jiang, Q., Li, Q., Arniego, P., Coleman, T.A., Lawrence, D.A., Chopp, M., Adjuvant treatment with neuroserpin increases the therapeutic window for tissue-type plasminogen activator administration in a rat model of embolic stroke. Circulation 106:6 (2002), 740–745.
40. [40] Gelderblom, M., Neumann, M., Ludewig, P., Bernreuther, C., Krasemann, S., Arunachalam, P., Gerloff, C., Glatzel, M., Magnus, T., Deficiency in serine protease inhibitor neuroserpin exacerbates ischemic brain injury by increased postischemic inflammation. PLoS One, 8(5), 2013, e63118.
41. [41] Wu, J., Echeverry, R., Guzman, J., Yepes, M., Neuroserpin protects neurons from ischemia-induced plasmin-mediated cell death independently of tissue-type plasminogen activator inhibition. Am. J. Pathol. 177:5 (2010), 2576–2584.
42. [42] Lebeurrier, N., Liot, G., Lopez-Atalaya, J.P., Orset, C., Fernandez-Monreal, M., Sonderegger, P., Ali, C., Vivien, D., The brain-specific tissue-type plasminogen activator inhibitor, neuroserpin, protects neurons against excitotoxicity both in vitro and in vivo. Mol. Cell. Neurosci. 30:4 (2005), 552–558.
43. [43] Yepes, M., Sandkvist, M., Coleman, T.A., Moore, E., Wu, J.Y., Mitola, D., Bugge, T.H., Lawrence, D.A., Regulation of seizure spreading by neuroserpin and tissue-type plasminogen activator is plasminogen-independent. J. Clin. Invest. 109:12 (2002), 1571–1578.
44. [44] Yepes, M., Sandkvist, M., Moore, E.G., Bugge, T.H., Strickland, D.K., Lawrence, D.A., Tissue-type plasminogen activator induces opening of the blood-brain barrier via the LDL receptor-related protein. J. Clin. Invest. 112:10 (2003), 1533–1540.
45. [45] Fredriksson, L., Stevenson, T.K., Su, E.J., Ragsdale, M., Moore, S., Craciun, S., Schielke, G.P., Murphy, G.G., Lawrence, D.A., Identification of a neurovascular signaling pathway regulating seizures in mice. Ann. Clin. Transl. Neurol. 2:7 (2015), 722–738.
46. [46] Su, E.J., Fredriksson, L., Geyer, M., Folestad, E., Cale, J., Andrae, J., Gao, Y., Pietras, K., Mann, K., Yepes, M., Strickland, D.K., Betsholtz, C., Eriksson, U., Lawrence, D.A., Activation of PDGF-CC by tissue plasminogen activator impairs blood-brain barrier integrity during ischemic stroke. Nat. Med. 14:7 (2008), 731–737.
47. [47] Simonin, Y., Charron, Y., Sonderegger, P., Vassalli, J.D., Kato, A.C., An inhibitor of serine proteases, neuroserpin, acts as a neuroprotective agent in a mouse model of neurodegenerative disease. J. Neurosci. 26:41 (2006), 10614–10619.
48. [48] Gu, R.P., Fu, L.L., Jiang, C.H., Xu, Y.F., Wang, X., Yu, J., Retina is protected by neuroserpin from ischemic/reperfusion-induced injury independent of tissue-type plasminogen activator. PLoS One, 10(7), 2015, e0130440.
49. [49] Parcq, J., Bertrand, T., Montagne, A., Baron, A.F., Macrez, R., Billard, J.M., Briens, A., Hommet, Y., Wu, J., Yepes, M., Lijnen, H.R., Dutar, P., Angles-Cano, E., Vivien, D., Unveiling an exceptional zymogen: the single-chain form of tPA is a selective activator of NMDA receptor-dependent signaling and neurotoxicity. Cell Death Differ. 19:12 (2012), 1983–1991.
50. [50] Bertrand, T., Lesept, F., Chevilley, A., Lenoir, S., Aimable, M., Briens, A., Hommet, Y., Bardou, I., Parcq, J., Vivien, D., Conformations of tissue plasminogen activator (tPA) orchestrate neuronal survival by a crosstalk between EGFR and NMDAR. Cell Death Dis., 6, 2015, e1924.
51. [51] Cheng, Y., Loh, Y.P., Birch, N.P., Neuroserpin attenuates H2O2-induced oxidative stress in hippocampal neurons via AKT and BCL-2 signaling pathways. J. Mol. Neurosci., 2016, 10.1007/s12031-016-0807-7.
52. [52] Rodriguez-Gonzalez, R., Millan, M., Sobrino, T., Miranda, E., Brea, D., de la Ossa, N.P., Blanco, M., Perez, J., Dorado, L., Castellanos, M., Lomas, D.A., Moro, M.A., Davalos, A., Castillo, J., The natural tissue plasminogen activator inhibitor neuroserpin and acute ischaemic stroke outcome. Thromb. Haemost. 105:3 (2011), 421–429.
53. [53] Ma, J., Yu, D., Tong, Y., Mao, M., Effect of neuroserpin in a neonatal hypoxic-ischemic injury model ex vivo. Biol. Res. 45:4 (2012), 357–362.
54. [54] Wang, L., Zhang, Y., Asakawa, T., Li, W., Han, S., Li, Q., Xiao, B., Namba, H., Lu, C., Dong, Q., Neuroprotective effect of neuroserpin in oxygen-glucose deprivation- and reoxygenation-treated rat astrocytes in vitro. PLoS One, 10(4), 2015, e0123932.
55. [55] Vawter, M.P., Barrett, T., Cheadle, C., Sokolov, B.P., Wood, W.H. 3rd, Donovan, D.M., Webster, M., Freed, W.J., Becker, K.G., Application of cDNA microarrays to examine gene expression differences in schizophrenia. Brain Res. Bull. 55:5 (2001), 641–650.
56. [56] Brennand, K.J., Simone, A., Jou, J., Gelboin-Burkhart, C., Tran, N., Sangar, S., Li, Y., Mu, Y., Chen, G., Yu, D., McCarthy, S., Sebat, J., Gage, F.H., Modelling schizophrenia using human induced pluripotent stem cells. Nature 473:7346 (2011), 221–225.
57. [57] Gooptu, B., Lomas, D.A., Conformational pathology of the serpins: themes, variations, and therapeutic strategies. Annu. Rev. Biochem. 78 (2009), 147–176.
58. [58] Roussel, B.D., Irving, J.A., Ekeowa, U.I., Belorgey, D., Haq, I., Ordonez, A., Kruppa, A.J., Duvoix, A., Rashid, S.T., Crowther, D.C., Marciniak, S.J., Lomas, D.A., Unravelling the twists and turns of the serpinopathies. FEBS J. 278:20 (2011), 3859–3867.
59. [59] Davis, R.L., Shrimpton, A.E., Holohan, P.D., Bradshaw, C., Feiglin, D., Collins, G.H., Sonderegger, P., Kinter, J., Becker, L.M., Lacbawan, F., Krasnewich, D., Muenke, M., Lawrence, D.A., Yerby, M.S., Shaw, C.M., Gooptu, B., Elliott, P.R., Finch, J.T., Carrell, R.W., Lomas, D.A., Familial dementia caused by polymerization of mutant neuroserpin. Nature 401:6751 (1999), 376–379.
60. [60] Hagen, M.C., Murrell, J.R., Delisle, M.B., Andermann, E., Andermann, F., Guiot, M.C., Ghetti, B., Encephalopathy with neuroserpin inclusion bodies presenting as progressive myoclonus epilepsy and associated with a novel mutation in the proteinase inhibitor 12 gene. Brain Pathol. 21:5 (2011), 575–582.
61. [61] Davis, R.L., Shrimpton, A.E., Carrell, R.W., Lomas, D.A., Gerhard, L., Baumann, B., Lawrence, D.A., Yepes, M., Kim, T.S., Ghetti, B., Piccardo, P., Takao, M., Lacbawan, F., Muenke, M., Sifers, R.N., Bradshaw, C.B., Kent, P.F., Collins, G.H., Larocca, D., Holohan, P.D., Association between conformational mutations in neuroserpin and onset and severity of dementia. Lancet 359:9325 (2002), 2242–2247.
62. [62] Ricagno, S., Caccia, S., Sorrentino, G., Antonini, G., Bolognesi, M., Human neuroserpin: structure and time-dependent inhibition. J. Mol. Biol. 388:1 (2009), 109–121.
63. [63] Takehara, S., Onda, M., Zhang, J., Nishiyama, M., Yang, X., Mikami, B., Lomas, D.A., The 2.1-A crystal structure of native neuroserpin reveals unique structural elements that contribute to conformational instability. J. Mol. Biol. 388:1 (2009), 11–20.
64. [64] Belorgey, D., Sharp, L.K., Crowther, D.C., Onda, M., Johansson, J., Lomas, D.A., Neuroserpin Portland (Ser52Arg) is trapped as an inactive intermediate that rapidly forms polymers: implications for the epilepsy seen in the dementia FENIB. Eur. J. Biochem. 271:16 (2004), 3360–3367.
65. [65] Kroeger, H., Miranda, E., MacLeod, I., Perez, J., Crowther, D.C., Marciniak, S.J., Lomas, D.A., Endoplasmic reticulum-associated degradation (ERAD) and autophagy cooperate to degrade polymerogenic mutant serpins. J. Biol. Chem. 284:34 (2009), 22793–22802.
66. [66] Davies, M.J., Miranda, E., Roussel, B.D., Kaufman, R.J., Marciniak, S.J., Lomas, D.A., Neuroserpin polymers activate NF-kappaB by a calcium signaling pathway that is independent of the unfolded protein response. J. Biol. Chem. 284:27 (2009), 18202–18209.
67. [67] Roussel, B.D., Newton, T.M., Malzer, E., Simecek, N., Haq, I., Thomas, S.E., Burr, M.L., Lehner, P.J., Crowther, D.C., Marciniak, S.J., Lomas, D.A., Sterol metabolism regulates neuroserpin polymer degradation in the absence of the unfolded protein response in the dementia FENIB. Hum. Mol. Genet. 22:22 (2013), 4616–4626.
68. [68] Ying, Z., Wang, H., Fan, H., Wang, G., The endoplasmic reticulum (ER)-associated degradation system regulates aggregation and degradation of mutant neuroserpin. J. Biol. Chem. 286:23 (2011), 20835–20844.
69. [69] Schipanski, A., Oberhauser, F., Neumann, M., Lange, S., Szalay, B., Krasemann, S., van Leeuwen, F.W., Galliciotti, G., Glatzel, M., Lectin OS-9 delivers mutant neuroserpin to endoplasmic reticulum associated degradation in familial encephalopathy with neuroserpin inclusion bodies. Neurobiol. Aging 35:10 (2014), 2394–2403.
70. [70] Moriconi, C., Ordonez, A., Lupo, G., Gooptu, B., Irving, J.A., Noto, R., Martorana, V., Manno, M., Timpano, V., Guadagno, N.A., Dalton, L., Marciniak, S.J., Lomas, D.A., Miranda, E., Interactions between N-linked glycosylation and polymerisation of neuroserpin within the endoplasmic reticulum. FEBS J. 282:23 (2015), 4565–4579.
71. [71] Saga, G., Sessa, F., Barbiroli, A., Santambrogio, C., Russo, R., Sala, M., Raccosta, S., Martorana, V., Caccia, S., Noto, R., Moriconi, C., Miranda, E., Grandori, R., Manno, M., Bolognesi, M., Ricagno, S., Embelin binds to human neuroserpin and impairs its polymerisation. Sci. Rep., 6, 2016, 18769.
72. [72] Selkoe, D.J., Toward a comprehensive theory for Alzheimer's disease. Hypothesis: Alzheimer's disease is caused by the cerebral accumulation and cytotoxicity of amyloid beta-protein. Ann. N. Y. Acad. Sci. 924 (2000), 17–25.
73. [73] Kinghorn, K.J., Crowther, D.C., Sharp, L.K., Nerelius, C., Davis, R.L., Chang, H.T., Green, C., Gubb, D.C., Johansson, J., Lomas, D.A., Neuroserpin binds Abeta and is a neuroprotective component of amyloid plaques in Alzheimer disease. J. Biol. Chem. 281:39 (2006), 29268–29277.
74. [74] Fabbro, S., Seeds, N.W., Plasminogen activator activity is inhibited while neuroserpin is up-regulated in the Alzheimer disease brain. J. Neurochem. 109:2 (2009), 303–315.
75. [75] Nielsen, H.M., Minthon, L., Londos, E., Blennow, K., Miranda, E., Perez, J., Crowther, D.C., Lomas, D.A., Janciauskiene, S.M., Plasma and CSF serpins in Alzheimer disease and dementia with Lewy bodies. Neurology 69:16 (2007), 1569–1579.
76. [76] Subhadra, B., Schaller, K., Seeds, N.W., Neuroserpin up-regulation in the Alzheimer's disease brain is associated with elevated thyroid hormone receptor-beta1 and HuD expression. Neurochem. Int. 63:5 (2013), 476–481.
77. [77] Fabbro, S., Schaller, K., Seeds, N.W., Amyloid-beta levels are significantly reduced and spatial memory defects are rescued in a novel neuroserpin-deficient Alzheimer's disease transgenic mouse model. J. Neurochem. 118:5 (2011), 928–938.
78. [78] Valiente, M., Obenauf, A.C., Jin, X., Chen, Q., Zhang, X.H., Lee, D.J., Chaft, J.E., Kris, M.G., Huse, J.T., Brogi, E., Massague, J., Serpins promote cancer cell survival and vascular co-option in brain metastasis. Cell 156:5 (2014), 1002–1016.
79. [79] Miles, L.A., Castellino, F.J., Gong, Y., Critical role for conversion of glu-plasminogen to Lys-plasminogen for optimal stimulation of plasminogen activation on cell surfaces. Trends Cardiovasc. Med. 13:1 (2003), 21–30.
80. [80] Barker-Carlson, K., Lawrence, D.A., Schwartz, B.S., Acyl-enzyme complexes between tissue-type plasminogen activator and neuroserpin are short-lived in vitro. J. Biol. Chem. 277:49 (2002), 46852–46857.
81. [81] Lee, T.W., Yang, A.S., Brittain, T., Birch, N.P., An analysis approach to identify specific functional sites in orthologous proteins using sequence and structural information: application to neuroserpin reveals regions that differentially regulate inhibitory activity. Proteins 83:1 (2015), 135–152.
82. [82] Carlson, K.S., Nguyen, L., Schwartz, K., Lawrence, D.A., Schwartz, B.S., Neuroserpin differentiates between forms of tissue type plasminogen activator via pH dependent deacylation. Front. Cell. Neurosci., 10, 2016, 154.
83. [83] Lindahl, T.L., Sigurdardottir, O., Wiman, B., Stability of plasminogen activator inhibitor 1 (PAI-1). Thromb. Haemost. 62:2 (1989), 748–751.
84. [84] Sashindranath, M., Sales, E., Daglas, M., Freeman, R., Samson, A.L., Cops, E.J., Beckham, S., Galle, A., McLean, C., Morganti-Kossmann, C., Rosenfeld, J.V., Madani, R., Vassalli, J.D., Su, E.J., Lawrence, D.A., Medcalf, R.L., The tissue-type plasminogen activator-plasminogen activator inhibitor 1 complex promotes neurovascular injury in brain trauma: evidence from mice and humans. Brain 135:Pt. 11 (2012), 3251–3264.
85. [85] Sarkar, A., Zhou, C., Meklemburg, R., Wintrode, P.L., Local conformational flexibility provides a basis for facile polymer formation in human neuroserpin. Biophys. J. 101:7 (2011), 1758–1765.